INmune Bio (INMB) Competitors $7.46 -0.22 (-2.86%) Closing price 04:00 PM EasternExtended Trading$7.69 +0.23 (+3.14%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. IMNM, AVBP, TRVI, PHAR, DAWN, DNTH, IOVA, EOLS, ABUS, and AKBAShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Immunome (IMNM), ArriVent BioPharma (AVBP), Trevi Therapeutics (TRVI), Pharming Group (PHAR), Day One Biopharmaceuticals (DAWN), Dianthus Therapeutics (DNTH), Iovance Biotherapeutics (IOVA), Evolus (EOLS), Arbutus Biopharma (ABUS), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Immunome ArriVent BioPharma Trevi Therapeutics Pharming Group Day One Biopharmaceuticals Dianthus Therapeutics Iovance Biotherapeutics Evolus Arbutus Biopharma Akebia Therapeutics Immunome (NASDAQ:IMNM) and INmune Bio (NASDAQ:INMB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, community ranking, media sentiment and profitability. Does the media prefer IMNM or INMB? In the previous week, Immunome had 7 more articles in the media than INmune Bio. MarketBeat recorded 8 mentions for Immunome and 1 mentions for INmune Bio. INmune Bio's average media sentiment score of 1.09 beat Immunome's score of 0.91 indicating that INmune Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive INmune Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is IMNM or INMB more profitable? INmune Bio has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. Immunome's return on equity of -48.63% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-3,014.59% -48.63% -41.62% INmune Bio N/A -117.48%-78.96% Does the MarketBeat Community favor IMNM or INMB? INmune Bio received 105 more outperform votes than Immunome when rated by MarketBeat users. However, 78.00% of users gave Immunome an outperform vote while only 76.60% of users gave INmune Bio an outperform vote. CompanyUnderperformOutperformImmunomeOutperform Votes3978.00% Underperform Votes1122.00% INmune BioOutperform Votes14476.60% Underperform Votes4423.40% Which has more risk & volatility, IMNM or INMB? Immunome has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, INmune Bio has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Do analysts recommend IMNM or INMB? Immunome presently has a consensus target price of $23.33, indicating a potential upside of 194.61%. INmune Bio has a consensus target price of $22.80, indicating a potential upside of 205.63%. Given INmune Bio's stronger consensus rating and higher probable upside, analysts clearly believe INmune Bio is more favorable than Immunome.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00INmune Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders and institutionals have more ownership in IMNM or INMB? 44.6% of Immunome shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 8.6% of Immunome shares are held by company insiders. Comparatively, 35.2% of INmune Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher earnings & valuation, IMNM or INMB? INmune Bio has lower revenue, but higher earnings than Immunome. INmune Bio is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$10.94M63.00-$106.81M-$3.18-2.49INmune Bio$50K3,429.21-$30.01M-$1.93-3.87 SummaryINmune Bio beats Immunome on 10 of the 19 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$171.46M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-3.4230.5026.8419.71Price / Sales3,429.21400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book3.603.286.794.50Net Income-$30.01M-$72.17M$3.23B$248.18M7 Day Performance0.40%4.28%4.07%1.14%1 Month Performance2.47%7.62%12.52%15.20%1 Year Performance-29.36%-28.15%16.83%6.56% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.9459 of 5 stars$7.46-2.9%$22.80+205.6%-31.6%$171.46M$50,000.00-3.4210Positive NewsGap DownIMNMImmunome2.6231 of 5 stars$7.94+6.4%$25.33+219.1%-38.0%$690.88M$9.04M-0.9840Gap DownAVBPArriVent BioPharma1.0129 of 5 stars$19.99-0.8%$39.00+95.1%+6.5%$680.56MN/A-7.7840Analyst ForecastTRVITrevi Therapeutics3.6055 of 5 stars$6.70+1.5%$17.56+162.1%+128.6%$669.28MN/A-15.2320News CoveragePositive NewsAnalyst ForecastPHARPharming Group1.653 of 5 stars$9.81-2.2%$30.00+206.0%+11.5%$667.04M$297.20M-37.71280Negative NewsGap UpDAWNDay One Biopharmaceuticals2.9161 of 5 stars$6.58+2.0%$30.57+364.6%-58.8%$666.96M$161.92M-6.3960DNTHDianthus Therapeutics1.2877 of 5 stars$20.08+2.5%$54.33+170.6%-24.9%$645.09M$6.24M-8.0380IOVAIovance Biotherapeutics4.4379 of 5 stars$1.93+10.3%$14.80+666.8%-81.5%$644.49M$212.68M-1.30500Trending NewsGap DownHigh Trading VolumeEOLSEvolus3.5838 of 5 stars$9.98+1.8%$23.75+138.0%-25.8%$643.42M$266.27M-10.97170Gap UpHigh Trading VolumeABUSArbutus Biopharma1.8887 of 5 stars$3.35+3.7%$5.50+64.2%+4.6%$641.46M$6.17M-7.7990Earnings ReportGap UpAKBAAkebia Therapeutics4.225 of 5 stars$2.43-4.7%$6.63+172.6%+153.9%$636.14M$160.18M-10.56430High Trading Volume Related Companies and Tools Related Companies Immunome Competitors ArriVent BioPharma Competitors Trevi Therapeutics Competitors Pharming Group Competitors Day One Biopharmaceuticals Competitors Dianthus Therapeutics Competitors Iovance Biotherapeutics Competitors Evolus Competitors Arbutus Biopharma Competitors Akebia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
